


CJJ300

Cat. No.:	HY-146693		
CAS No.:	1807631-83-9		
Molecular Formula:	C ₃₀ H ₃₃ N ₃		
Molecular Weight:	435.6		
Target:	TGF-β Receptor		
Pathway:	TGF-beta/Smad		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (229.57 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2957 mL	11.4784 mL	22.9568 mL
		5 mM	0.4591 mL	2.2957 mL	4.5914 mL
10 mM		0.2296 mL	1.1478 mL	2.2957 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.74 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC ₅₀ of 5.3 μM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex ^[1] .
IC₅₀ & Target	IC ₅₀ : 5.3 μM (TGF-β1-induced luciferase) ^[1]
In Vitro	CJJ300 disturbs protein-protein interactions and prevents TGF-β receptor dimerization (IC ₅₀ = 23.6 ± 5.8 μM) ^[1] . CJJ300 (0-80 μM, 2 h) inhibits the phosphorylation of intracellular mediators in the downstream TGF-β signaling pathways, and suppresses the expression of markers of EMT (epithelial-mesenchymal transition) without cytotoxicity ^[1] . CJJ300 suppresses TGF-β induced cell migration ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]

Cell Line:	Human A549 lung epithelial cells
Concentration:	20, 40, and 80 μ M
Incubation Time:	2 h
Result:	Significantly attenuated the increase of P-Smad2/Smad3, P-Erk1/2 and P-Akt induced by TGF- β . Down regulated the expression of EMT-associated proteins, including fibronectin, α -SMA and MMP-2 in a dose-dependent manner.

REFERENCES

[1]. Han Wu, et al. The development of a novel transforming growth factor- β (TGF- β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020 Mar 1;189:112042.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA